This company had SEC problems with the founder, but according to Colette Cozean, Ph.D Director of the Board, Surgilight has settled all problems with the SEC and are ready to resume shareholder meetings. They own 16 patents for presbyopia reversal and have FDA approved lasers for leasing out to doctors. Presbyopia is the degeneration of the eyes for reading, which eventually affects most people over 40.

This company has just received the European FDA approval (CE) and have already been selling their process in Asia. They are at Clinical Stage II for the US. On their website, there is a schedule of conferences and teaching seminars that their salespeople will be attending in 2006.

Stock is at an all time low of $0.015/share. The volume is light on alternate days, but blocks of 5,000 and 10,000 shares are fairly easy to get. This stock is on the same path as Visx back in the 90's. Check out their annual filings with the SEC. Their webite is www.surgilight.com.